Concerning a potential application of our findings for the treatment of RA, therapeutic application of TLR9 antagonists might be considered in the very early pre‐clinical phases in persons at high risk for developing RA to prevent (further) generation of harmful autoimmune reactions leading to the inflammatory and deleterious processes in the joint characteristic of RA. Here, TLR9 is linked to rheumatoid arthritis.